Sunshine Biopharma Inc
NASDAQ:SBFM

  • LAST PRICE
    2.4400
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    2.3600/ 6
  • Ask / Lots
    2.5000/ 1
  • Open / Previous Close
    --- / 2.4400
  • Day Range
    ---
  • 52 Week Range
    2.1056
    637.2000
  • Volume
    1,896

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 22, 2024

  • Nov 6, 2024

      Show headlines and story abstract

    • 8:04AM ET on Wednesday Nov 06, 2024 by MT Newswires
      Companies Mentioned: SBFM
      08:04 AM EST, 11/06/2024 (MT Newswires) -- ...

    • 8:02AM ET on Wednesday Nov 06, 2024 by Dow Jones
      Companies Mentioned: SBFM

      FORT LAUDERDALE, FL / ACCESSWIRE / November 6, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2024 third quarter report with the Securities and Exchange Commission. The Company reported gross revenues of $8,435,178 for the three months ended September 30, 2024, a 42% increase over gross revenues of $5,957,668 for same period in 2023. For the nine-month period ended September 30, 2024, gross revenues were $25,279,291, compared to gross revenue of $16,412,586 for the same period in 2023, an increase of 54%. These increases were a result of new product launches and expanded marketing and sales efforts by the Company's wholly owned Canadian subsidiary, Nora Pharma Inc.

    • 8:02AM ET on Wednesday Nov 06, 2024 by Dow Jones
      Companies Mentioned: SBFM

      FORT LAUDERDALE, FL / ACCESSWIRE / November 6, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2024 third quarter report with the Securities and Exchange Commission. The Company reported gross revenues of $8,435,178 for the three months ended September 30, 2024, a 42% increase over gross revenues of $5,957,668 for same period in 2023. For the nine-month period ended September 30, 2024, gross revenues were $25,279,291, compared to gross revenue of $16,412,586 for the same period in 2023, an increase of 54%. These increases were a result of new product launches and expanded marketing and sales efforts by the Company's wholly owned Canadian subsidiary, Nora Pharma Inc.

Peers Headlines